the dietary recommendations for essential fatty acids (EFA); discuss the scientific evidence for the roles of EFA in cognition, immune function and cardiovascular health; and to identify opportunities for joint efforts by industry, academia, governmental and nongovernmental organizations to effectively improve health behaviour. This paper summarizes the main conclusions of the presentations given at the symposium. Linoleic acid (LA) and a-linolenic acid (ALA) are EFA that cannot by synthesized by the human body. Docosahexaenoic acid (DHA) is considered as conditionally essential because of its limited formation from ALA in the human body and its critical role in early normal retinal and brain development and, jointly with eicosapentaenoic acid (EPA), in prevention of cardiovascular disease (CVD). Some evidence for possible beneficial roles of n-3 fatty acids for immune function and adult cognitive function is emerging. A higher consumption of polyunsaturated fatty acids (PUFA; 410%E), including LA, ALA and at least 250-500 mg per day of EPA þ DHA, is recommended for prevention of coronary heart disease (CHD). Two dietary interventions suggest that EFA may affect CVD risk factors in children similarly as in adults. To ensure an adequate EFA intake of the population, including children, public health authorities should develop clear messages based on current science; ensure availability of healthy, palatable foods; and collaborate with scientists, the food industry, schools, hospitals, health-care providers and communities to encourage consumers to make healthy choices.
Introduction
Fatty acids that cannot be synthesized by humans, that is, necessary to be obtained from the diet, are referred to as 'essential' fatty acids (EFA). These include the polyunsaturated fatty acids (PUFA), n-6 linoleic acid (LA, ) from vegetable oils and n-3 a-linolenic acid (ALA, 18:3n-3) from plant sources (flaxseed, rapeseed oil, walnuts, soybean oil). The n-3 PUFA, found in fish and shellfish, eicosapentaenoic acid (EPA, 20:5n-3) and docosahexaenoic acid (DHA, 22:6n-3) can be synthesized from ALA and thus formally are not 'essential' fatty acids. However, synthesis of EPA and especially DHA is extremely limited in humans (o5-6 and o0.1% conversion from ALA, respectively; Harris et al., 2009a) and the rate of conversion is further reduced in a substantial portion of the populations that carries genetic variants of the fatty acid desaturase gene cluster (Glaser et al., 2010; Lattka et al., 2010a) . At present, it remains unclear whether this endogenous conversion of parent EFA to their long-chain metabolites is sufficient for optimal health. Thus, EPA and especially DHA may be considered to be conditionally essential, that is, necessary to obtain from the diet. Sufficient intakes of PUFA during childhood are required for optimal growth and development and for prevention of the onset of chronic disease in later life. Consumption of a healthy diet that includes PUFA throughout the life is important to maintain cardiovascular and possibly also cognitive and immune health (WHO/FAO, 2003) . In most populations, current intakes of PUFA and especially n-3 PUFA are insufficient for optimal health (Elmadfa and Kornsteiner, 2009) . Therefore, researchers, policy-makers and the food industry must work together in translating the science and dietary guidelines for PUFA into practical coherent dietary recommendations and high-quality products that allow people to improve the fat quality of their diets and benefit their health.
The 9 th Unilever Nutrition Symposium entitled 'Essential fats for future health' was held on 26-27 May 2010, with objectives of (1) reviewing the health effects of n-3 and n-6 PUFA in children and adults, including cognitive development and performance, immune function, and cardiovascular health; (2) addressing gaps in PUFA intakes versus recommendations for different age groups; and (3) identifying opportunities for joint efforts by academia, industry, governmental and non-governmental organizations to effectively improve health behaviour with regard to a sustained, desirable intake of PUFA including EFA. The symposium consisted of three sessions, including (1) Requirements and recommendations; (2) Benefits of essential fats for future health; and (3) Joint solutions for future health. This paper summarises the main conclusions of the presentations given at the symposium.
Session 1. Requirements and Recommendations
The first session was an introductory session aiming to clarify the roles of PUFA including EFA in the body, which was presented by Professor Ricardo Uauy. In addition, an overview on the latest fatty acid recommendations for prevention of cardiovascular disease (CVD) was provided by Dr Dariush Mozaffarian.
EFA requirements: how much do we really need-Professor Ricardo Uauy
Fats have traditionally been considered a necessary part of the dietary energy supply. Until recently, the main focus of research has been on the total amount of fat that can be tolerated and digested by infants and young children, although the composition of dietary fat had received relatively less attention. Interest in the quality of dietary fat supply in early life as a major determinant of growth, infant development and long-term health is presently growing. Indeed, the selection of dietary fat and fatty acid sources during the first years of life is now considered to be of critical importance. Fats enhance the taste and acceptability of foods; fat components determine, in large part, the texture, flavour and aroma of foods. In addition, fats slow gastric emptying and intestinal motility, thereby affecting satiety. Dietary fats provide EFA and facilitate the absorption of fat-soluble vitamins. Fats are the main energy source in the infant diet and are therefore necessary for normal growth and physical activity. Indeed, fats provide around half of the energy in human milk and in most infant formulas. Finally, fat also constitutes the major energy store in the body; the energy content of adipose tissue on a wet weight basis is 7-8-fold higher than that of tissue containing glycogen or protein.
EFA deficiency, synthesis and metabolism
In 1929, George and Mildred Burr (Burr and Burr, 1973) introduced the concept that specific components of fat may be necessary for normal growth and development of animals and possibly humans. They proposed that three specific fatty acids be considered as essential: LA, arachidonic acid (AA, 20:4n-6) and ALA. Despite this important early work, EFA largely ignored in human nutrition until the 1960s, when signs of clinical deficiency were first noted in infants fed skim milk-based formula and in neonates given fat-free parenteral nutrition. These seminal observations firmly established that LA is essential for normal infant nutrition. Hansen et al. (1963) observed dryness, desquamation and thickening of the skin, and growth faltering as clinical manifestations of LA deficiency in young infants. More subtle symptoms appeared in n-3 EFA deficiency including skin changes unresponsive to LA supplementation, abnormal visual function and peripheral neuropathy; these have been reported in subjects receiving high n-6, low n-3 fat sources as part of their intravenous nutrition supply (Holman et al., 1982) .
Humans can synthesize saturated and monounsaturated fatty acids, but not the n-3 and the n-6 families of PUFA. Thus, the parent EFA, ALA and LA, respectively, must be present in the diet. The essentiality of EFA for humans is best explained by the inability of animal tissues to introduce double bonds in positions proximal to carbon 9, counting from the methyl or N-terminus. Moreover, the respective n-3 and n-6 EFA cannot be interconverted, thereby making both essential. ALA and LA can be converted to longer chain PUFA (LCPUFA) through enzymatic chain elongation and desaturation. ALA is converted to EPA and then to DHA, whereas LA is converted to AA. DHA is a critical component of cell membranes, especially relevant for the functioning of retina and brain. The high DHA relative content of cerebral cortex and retinal phospholipids supports an essential role of this n-3 fatty acid for brain and visual functions (Uauy and Hoffman, 1991) , and it is also possible that nervous system manifestations of n-3 deficit may result from DHA deficit. AA is both a membrane component and a precursor to potent signalling molecules, the prostaglandins and leukotrienes.
The chain elongation/desaturation enzymes are shared by the n-3 and n-6 fatty acids leading to competition between substrates. However, synthesis of n-6 LCPUFA from LA in early life seems to be more efficient than that of n-3 fatty acids.
Typically, cell membranes from animal or human tissues deficient in n-3 fatty acids have decreased levels of DHA and increased levels of the end product of n-6 metabolism, n-6 docosapentaenoic acid (DPA, . Within the subcellular organelles, synaptosomes and mitochondria seem to be the most sensitive to a low dietary n-3 supply, as evidenced by the relative abundance of DHA in these organelles and their response to dietary deprivation.
Human neonates as young as 28 weeks gestation weighing 900 g are able to synthesize LCPUFA from their precursors. However, this conversion is quite limited (3-5% of a tracer dose of labelled precursors was found to be converted to LCPUFA over a 96 h period), and the overall evidence indicates that in early life, ALA is not sufficiently converted to DHA to allow for biochemical and functional normalcy (Salem et al., 1996) . Moreover, recent studies of genetic polymorphisms in genes responsible for fatty acid desaturation suggest that variability in biochemical responses and functional central nervous system effects to changes in diet are partly explained by single-nucleotide polymorphisms affecting a large proportion of the population (Caspi et al., 2007) .
The uniqueness of the biological effects of feeding human milk on EFA metabolism is based on the direct supply of preformed LCPUFA, bypassing the regulatory step of both the delta-6 and delta-5 desaturases. Excess dietary LA associated with some vegetable oils, particularly safflower, sunflower and corn oil, may decrease the formation of DHA from ALA because the delta-6 desaturase is inhibited by excess n-6 substrates. In addition, on a relative basis, AA formation is lower when excess LA is provided. The inhibitory effect of EPA on delta-5 desaturase activity has been considered responsible for the lower membrane and plasma AA content observed when marine oil is consumed. Excess LA, as seen in infants receiving corn oil or safflower oil as the predominant fatty acid supply, will inhibit the elongation and desaturation of the parent EFA and thus lower the LCPUFA supply available for membrane synthesis. Human milk and LCPUFA from most non-marine food sources provide minimal preformed DHA.
LA and ALA should be considered essential and indispensable as they cannot be synthesized by humans. Although DHA and AA can be synthesized from ALA and LA, respectively, they should be considered non-essential though a dietary supply may be necessary for long-term health. However, given the limited and highly variable formation of DHA from ALA (1-5%) and because of its critical role in normal retinal and brain development in the human, DHA should be considered conditionally essential during early development. Similarly, EPA þ DHA might be considered conditionally essential for life-long health considering intakes required for the prevention of CVD.
Essential fats for prevention of CVD-Dr Dariush Mozaffarian
Setting fatty acid guidelines Inconsistencies across different dietary fatty acid guidelines appear related to the absence of transparent and consistent methods for evaluating scientific evidence (Smit et al., 2009) . Several types of evidence are available, including that from the randomized controlled trials (RCTs), prospective cohort studies, retrospective case-control studies, ecological studies, cross-sectional studies, case series or reports and animal studies. For setting dietary guidelines, it is essential that strengths and limitations of the different study designs be explicitly considered when determining whether these are optimal for setting dietary guidelines.
As previously reviewed, these different study designs each have unique strengths and limitations (Smit et al., 2009) . Animal experiments, cross-sectional studies and ecological studies are useful for hypothesis generation. RCTs of physiological measures (intermediate end points or risk factors for disease) are important for supporting evidence. Prospective cohort studies and RCTs of disease outcomes provide the most direct evidence for effects of dietary fatty acids on chronic disease. Prospective cohort studies have many strengths, but a major potential limitation is the inability to exclude residual confounding. In contrast, the major strength of properly executed RCTs is minimization of confounding, but many other study design limitations can limit the utility of the results. A comparison of the strengths and limitations of RCTs versus prospective cohorts demonstrates their complementary nature; thus, inference regarding health effects of specific dietary factors can be considered strongest when both types of designs provide concordant results. When RCTs of disease outcomes are not available, RCTs of physiological measures can provide concordant evidence with prospective cohorts studies for effects on disease risk.
Convincing evidence for setting dietary fatty acid requirements is derived from concordant evidence from wellconducted RCTs of disease outcomes, prospective cohort studies of disease outcomes and RCTs of physiological measures. Given the challenges of performing well-conducted dietary trials of chronic disease outcomes, convincing evidence can also be derived from concordant evidence from well-conducted prospective cohort studies of disease outcomes and RCTs of physiological measures, when there is overall consistency and little evidence to the contrary. This framework is consistent with evidence statements from the World Health Organization (WHO; WHO/FAO, 2003) and the World Cancer Research Fund/American Institute for Cancer Research (2007) .
The scientific evidence for cardiovascular effects of the seafood-derived n-3 fatty acids, EPA þ DHA, and the plantderived n-3 and n-6 fatty acids is described below.
Seafood-derived n-3 PUFA RCTs demonstrate clear benefits of EPA þ DHA on heart rate, blood pressure and triglyceride levels and also the likely benefits on myocardial relaxation and efficiency, inflammatory responses, endothelial function, autonomic tone and urine proteinuria (Mozaffarian and Rimm, 2006; Mozaffarian, 2007; Peoples et al., 2008) . Animal experiments, including non-human primates, also demonstrate clear anti-arrhythmic effects (McLennan, 2001) , although small trials of prevention of recurrent ventricular tachyarrhythmia in patients with implantable cardiodefibrillators have been inconsistent (Brouwer et al., 2009) . Large prospective cohort studies and RCTs provide more direct evidence for effects on clinical end points. Nearly 20 prospective cohort studies have reported on fish consumption and cardiac death, and five RCTs have evaluated effects of fish or fish oil consumption on cardiovascular events. Meta-analyses of observational data consistently indicate that n-3 LCPUFAs are associated with lower incidence of fatal coronary heart disease (CHD; Mozaffarian and Rimm, 2006; Wang et al., 2006; Mente et al., 2009; Harris et al., 2009a) . Additionally, four of five large RCTs of fish or fish oil intake have demonstrated significant reductions in CHD events (Harris et al., 2009a) . In a meta-analysis of RCTs that included mostly high-risk populations, EPA þ DHA supplementation reduced total mortality by 17% (relative risk (RR) ¼ 0.83, 95% confidence interval (CI) ¼ 0.68-1.00; Po0.05); reductions in total mortality would be more modest in populations at lower risk of ischemia-induced arrhythmic death (Mozaffarian and Rimm, 2006) . The dose response for preventing CHD death appears non-linear, with 36% risk reduction (Po0.001) at B250 mg per day EPA þ DHA and then decreasing benefits thereafter (Mozaffarian and Rimm, 2006) . Benefits for other end points such as non-fatal myocardial infarction, ischemic stroke and atrial fibrillation are suggested by observational studies but are not yet clearly established from RCTs (Mozaffarian and Rimm, 2006; Wang et al., 2006; Harris et al., 2009a) . Because most studies have assessed combined intakes of EPA þ DHA, insufficient evidence exists to make recommendations about EPA versus DHA separately. Overall, the evidence is convincing that modest consumption of fish or fish oil reduces CHD death, and may favorably affect other clinical outcomes.
Plant-derived n-3 PUFA Consumption of the plant-derived n-3 fatty acid ALA may also reduce cardiovascular risk, but the evidence is not yet as strong or convincing as for EPA þ DHA. In a handful of RCTs, ALA consumption has favourably affected some cardiovascular risk markers, for example, related to platelet function, inflammation, endothelial function and arterial compliance (Mozaffarian, 2005) . A meta-analysis of 14 trials of ALA supplementation found improvements in fibrinogen and fasting glucose (Wendland et al., 2006) . Whether such effects are caused directly by ALA or by its (limited) conversion to EPA is unclear. Ecological studies suggest benefits of increasing ALA intake in populations with low overall n-3 PUFA consumption (Zatonski et al., 2008) . Results of prospective cohort studies of ALA and CVD have been mixed, with some individual studies observing inverse associations with CHD events but meta-analyses showing no significant overall relationship (Brouwer et al., 2004; Mozaffarian, 2005; Wang et al., 2006; Mente et al., 2009) . Only one RCT of ALA supplementation and CHD events has been completed: no significant effects were seen, but follow-up was limited to only 1 year (Mozaffarian, 2005) . Overall, there is currently only possible evidence that ALA consumption prevents CVD. Because ALA is an accessible and inexpensive source of n-3 PUFA, further investigation of these effects is essential, and several trials are planned or are ongoing.
n-6 PUFA LA is the major dietary PUFA, typically comprising 490% of dietary PUFA. RCTs demonstrate clear benefits of LA on blood lipid concentrations, including lowering the levels of low-density lipoprotein (LDL) cholesterol and triglycerides, the total/high-density lipoprotein (HDL) cholesterol ratio, and increasing the level of HDL cholesterol (Mensink et al., 2003) . Some trials suggest that LA may also be antiinflammatory or improve insulin resistance, but findings have been mixed (Galgani et al., 2008; Riserus et al., 2009; Harris et al., 2009b) . In a pooled analysis of 11 prospective cohorts, greater PUFA intake in place of saturated fat was associated with significantly lower incidence of CHD (for each 5%E, RR ¼ 0.87, 95% CI ¼ 0.77-0.97; Jakobsen et al., 2009) . Consistent with this, a meta-analysis of RCTs demonstrated similar reduction in CHD events when PUFA replaced saturated fat (for each 5%E, RR ¼ 0.90, 95% CI ¼ 0.83-0.97; Mozaffarian et al., 2010) . PUFA intake has also been associated with lower CHD risk when replacing carbohydrate (Oh et al., 2005) . These different lines of research provide strong concordant evidence that LA consumption lowers CHD risk, whether in place of saturated fat or carbohydrate. Because both n-3 and n-6 PUFA are beneficial, the ratio of n-6 to n-3 fatty acids is not a useful metric of health effects (Mozaffarian, 2005; Griffin, 2008; Harris et al., 2009b) .
On the basis of this evidence for health effects of n-3 and n-6 PUFA, current recommendations for an upper limit of PUFA consumption at 10% energy need to be revisited, and policy measures should prioritize higher consumption of both EPA þ DHA and LA (and probably ALA) in the population.
Session 2. Benefits of essential fats for future health
The second session focused on the current state of the scientific evidence for specific health effects of not only EFA LA and ALA but also their long-chain derivates, including AA, EPA and DHA. The session started with a presentation by Professor Berthold Koletzko who evaluated the data on the importance of fatty acid intake during pregnancy and lactation for infant growth and development. Dr Alan Dangour reviewed the evidence on the effects of n-3 fatty acids for improving cognition in children and older people, and Professor Philip Calder continued with the evidence of fatty acids in relation to immune function. The session ended with an overview on the effects of EFA intake during childhood on the development of cardiovascular health later in life by Dr Saskia Osendarp, which was illustrated with a presentation by Dr Harry Niinikoski on the results of the Special Turku coronary Risk factor Intervention Project (STRIP).
The role of long-chain omega 3 fatty acids in pregnancy, lactation and infancyProfessor Berthold Koletzko
Intrauterine and postnatal growth requires a high supply of essential n-6 and n-3 PUFA. These are precursors of LCPUFA, in particular AA, EPA and DHA. Endogenous LCPUFA synthesis by mothers, fetuses and infants is limited. Moreover, common polymorphisms in the FADS gene cluster have strong effects on LCPUFA synthesis, therefore, some individuals have a lower ability than others to form LCPUFA from dietary precursors supplied with vegetable oils (Lattka et al., 2010a (Lattka et al., , 2010b . DHA is rapidly deposited in brain and retina during early growth. Meta-analyses of randomized trials providing pregnant women with placebo or with oils providing DHA or EPA þ DHA showed a reduction by 31% in premature births o34 weeks in the total population, and by 61% in at-risk pregnancies . No relevant adverse effects were found at up to 1 g DHA per day, 2.7 g n-3 LCPUFA per day or 5 g fish oil per day. Perinatal DHA supply was also associated with benefits for infant development. In utero, the human fetus is supplied with preformed DHA by preferential placental transfer mediated by specific fatty acid transfer proteins. Maternal DHA supply enhances the DHA content of infant cord blood at birth and of human breast milk, which is associated with DHA accretion in infant brain and other tissues, and functional outcomes. Several observational and controlled intervention studies associated the degree of DHA supply to pregnant and lactating women, and to infants, to the child's visual development, fine motor function, social skill scores, language discrimination and verbal intelligent quotient up to school age Koletzko et al., 2008) . Maternal DHA supply during pregnancy also appears to modulate the infant's immune response and to lower the allergy risk (Krauss-Etschmann et al., 2008) . Recent evidencebased consensus recommendations on dietary fat supply for pregnant and lactating women, developed with support from the European Commission and endorsed by several international scientific organizations, concluded that pregnant and lactating women should aim at achieving an average DHA intake of at least 200 mg DHA per day (Koletzko et al., 2007) . This level of intake can usually be reached by 1-2 meals of ocean fish per week if fatty fish is included (for example, herring, mackerel, salmon, sardines). Women who do not achieve this level of regular fish consumption should consider using DHA supplements or DHA-enriched foods. The acceptable intake in pregnancy and lactation was defined by the European Food Safety Authority as 100-200 mg DHA in addition to the general adult acceptable intake of 250 mg n-3 LCPUFA (EFSA Panel on Dietetic Products, Nutrition and Allergies, 2010).
Essential fats for future cognitive healthDr Alan Dangour n-3 and n-6 PUFA have crucial roles in brain development in utero and in early infancy (Uauy and Dangour, 2006) . Some epidemiological evidence from early childhood, such as that from the Avon Longitudinal Study of Parents and Children, suggests that fish consumption by mothers during pregnancy is associated with enhanced behaviour and cognitive function in children (Hibbeln et al., 2007) . However, the evidence from RCTs is inconsistent. Maternal supplementation with 803 mg EPA þ 1183 mg DHA from 18 weeks of gestation to 3 months postpartum was associated with improved child cognitive function at 4 years, but not at 3 , 6 months or 7 years (Helland et al., 2001 (Helland et al., , 2003 (Helland et al., , 2008 , and supplementation of 8-10-year-old children with 200 mg EPA þ 83 mg DHA for 16 weeks had no effect on cognitive function (Kirby et al., 2010) . Even among 6-10-year-old children potentially at-risk of poor nutrition living in urban Jakarta, supplementation for 12 months with 22 mg EPA þ 88 mg DHA was not effective in enhancing cognitive function (Osendarp et al., 2007) . Of late, supplementation of 8-10-year-old boys with DHA (400 mg or 1.2 g per day for 8 weeks) was found to significantly increase activation of the dorsolateral prefrontal cortex, although the significance of this effect for cognitive function remains unclear (McNamara et al., 2010) .
In adults, n-3 LCPUFA have long been thought to be important for the prevention of cognitive decline and dementia, and there is a growing body of mechanistic evidence to suggest an important role of DHA in neuronal health (Bazan, 2006; Cole and Frautschy, 2010) . Several, although not all, longitudinal studies have identified positive associations between fish or n-3 LCPUFA consumption and cognitive health (Barberger-Gateau et al., 2002; Schaefer et al., 2006; Albanese et al., 2009) . A Cochrane review published in 2006 was unable to identify a single RCT evaluating the effect of EPA or DHA supplementation on cognitive function in older people (Lim et al., 2006) . Recently, however, two RCTs have been published. Van de Rest et al. (2008) identified no benefits to cognitive function of supplementation with low-dose (400 mg EPA þ DHA per day) or high-dose (1.8 g EPA þ DHA per day) EPA þ DHA for 6 months. In a significantly larger study, Dangour et al. (2010) randomized 867 cognitively healthy participants aged 70-79 years at baseline to either 200 mg EPA þ 500 mg DHA or olive oil placebo for 24 months. Despite significant differences in n-3 PUFA composition of plasma lipids between study arms at the end of the study, intervention with EPA þ DHA had no effect on cognitive function.
It is possible that supplementation with n-3 PUFA does not improve cognitive function in childhood or benefit cognitive health in later life. However, there are also other possible reasons for the lack of a positive effect of supplementation from the few available RCTs. The existing trials could be too short to show benefit, the individuals supplemented may be replete in n-3 fatty acids such that extra supplementation may not be of benefit, and it may be that any effect may be limited to individuals with particular variants of the genes that encode enzymes involved in the metabolism of PUFA, such as the fatty acid desaturases (Tanaka et al., 2009) . It is estimated that by 2040, 81 million people worldwide will suffer from dementia (Ferri et al., 2005) ; further studies investigating the factors determining the effectiveness of n-3 fatty acids in preserving cognitive health in later life remains a worthwhile endeavour.
Essential fats for future immune healthProfessor Philip Calder
The immune system acts to protect the host from pathogens and from other environmental insults. It has four key activities: being a barrier to pathogen entry; identification of 'non-self'/tolerance of 'self'; elimination of 'non-self'; and memory (Cummings et al., 2004) . The immune system includes many different cell types each with their own specific functions and roles and which act in a coordinated and integrated manner (Cummings et al., 2004) . A breakdown or dysfunction in one (or more) of the key activities of the immune system can result in disease. Inflammation is often a feature of such disease and can be damaging to the host . The complexity of the immune response, the large number of cells and functions involved, and the redundancies that exist mean that there is no single marker of the 'immune response' or of 'immune function' (Albers et al., 2005) . This has made it difficult to identify with certainty the effects of fatty acids on the immune response, although many effects of fatty acids have been reported upon specific components of the response. It is known that EFA deficiency impairs cellular aspects of the immune response (Harbige, 2003) . Incorporation of certain fatty acids into immune cell membranes can affect membrane structure and function including raft formation and signalling processes leading to gene expression, and can alter the profile of lipid mediators being produced (Shaikh and Edidin, 2006; Yaqoob and Calder, 2007; Calder, 2008; Kim et al., 2010) . These events have been most thoroughly studied in the context of marine n-3 fatty acids. Effects of fatty acids, especially marine n-3 fatty acids, on phagocytosis, respiratory burst, antigen presentation, T-cell reactivity, immunoglobulin production, cytokine production and lipidmediator production have all been demonstrated (Calder, 2001 (Calder, , 2007 Calder et al., 2002) . However, it is not always clear how these effects might translate into a more or less robust immune response in vivo and into an altered risk of infectious or inflammatory disease. Data from the Physician's Health Study showed a protective effect of increased intake of either LA or ALA towards community-acquired pneumonia; there was no significant effect of marine n-3 fatty acid intake (Merchant et al., 2005) . An intervention study with marine n-3 fatty acids in Thai schoolchildren found a reduction in infectious illness, mainly upper respiratory tract infections (Thienprasert et al., 2009) . Studies with marine n-3 fatty acids in pregnancy or infancy demonstrate some immune effects (Dunstan et al., 2003a (Dunstan et al., , 2003b Denburg et al., 2005; Damsgaard et al., 2007) and there is substantial literature suggesting an association between early fish or marine n-3 fatty acid exposure and reduced risk of allergic disease in children (Kremmyda et al., 2009) . The role of the n-6 fatty acid AA as a precursor for inflammatory eicosanoids suggests that n-6 fatty acids are likely to be pro-inflammatory, whereas n-3 fatty acids, which act to antagonize AA metabolism (Calder, 2006) , are likely to be anti-inflammatory. However, this seems to be an oversimplification as some studies find inverse associations between both n-6 and n-3 fatty acid intake or status and circulating inflammatory marker concentrations (FernandezReal et al., 2003; Lopez-Garcia et al., 2004; Ferrucci et al., 2006 ). An intervention study increasing LA intake from 7.7 to 12.6% energy found a limited effect of inflammatory markers (Zhao et al., 2004) , whereas increasing ALA intake can lower inflammatory marker concentrations and the response of inflammatory cells to stimulation (Burdge and Calder, 2006) . Two studies that demonstrate an anti-inflammatory effect of high intakes of ALA (Caughey et al., 1996; Zhao et al., 2004) suggest that the effect is likely due to conversion of ALA to the more biologically active EPA. Marine n-3 fatty acids have been shown to have anti-inflammatory effects, although these are variable between studies (Calder, 2006; Sijben and Calder, 2007) . Reasons for such variation likely include differences in the dose of n-3 fatty acids administered, duration of administration, characteristics of subjects studied including genetic differences, sample size, and relative amounts of EPA and DHA provided. Fish oil, which is rich in marine n-3 fatty acids, is effective in rheumatoid arthritis . Overall it appears that a balanced supply of n-6 and n-3 fatty acids and an appropriate supply of marine n-3 fatty acids are important for the immune system to respond appropriately. However, at the present time, it is not possible to state the amounts of different fatty acids that are required for an optimal immune response.
Essential fats for future cardiovascular healthDr Saskia Osendarp
CVD risk factors, such as obesity, unfavourable blood lipid profiles and high blood pressure, are now increasingly being observed in children. Globally in 2010, an estimated 42 million children under the age of 5 years were classified overweight or obese and more than 75% of these children were living in low-and middle-income countries (World Health Organization, 2010). High total and LDL cholesterol and triglyceride levels, and high blood pressure have been observed in cohorts in the US, Finland and Chile in children from as early as 4 years of age (Viikari et al., 1988; Berenson et al., 1998; McGill et al., 2001; Ford et al., 2009; Corvalan et al., 2010) .
In children, like in adults, CVD risk factors are associated with the extent of atherosclerosis: in autopsy data from children with multiple CVD risk factors, a larger percentage of the intimal surface was covered by fibrous plaques compared with children with no CVD risk factors (Berenson et al., 1998) . Overall, 50% of children had fatty streaks and 8% had fibrous-plaque lesions in the coronary arteries (Berenson et al., 1998) .
Data from longitudinal cohort studies suggest that CVD risk factors tend to track from childhood into adulthood (Webber et al., 1991; Chen and Wang, 2008; Raghuveer, 2010) . However, the strength of evidence and predictive value seem to depend on the type and severity of CVD risk factor. In a recent analysis, data from three major studies were combined to estimate the predictive values of childhood metabolic syndrome for metabolic syndrome and type 2 diabetes during adulthood. The negative, but not positive, predictive value of childhood metabolic syndrome was strong for type 2 diabetes and adult metabolic syndrome. The authors suggested that measurements of metabolic syndrome during childhood may therefore be particularly useful to identify children not at risk (Schubert et al., 2009) .
Positive associations are observed between childhood CVD risk factors and carotid intima-media thickness and arterial stiffness in adulthood (Davis et al., 2001; Li et al., 2003 Li et al., , 2004 . Evidence from a limited number of cases in one longitudinal cohort (Morrison et al., 2007) suggests that pediatric metabolic syndrome, defined as X3 abnormal CVD risk factors during childhood, is predictive for adult CVD events (odds ratio ¼ 14.6; 95% CI ¼ 4.8-45.3).
Role of fatty acids on CVD risk factors in children Similar to adults, dietary saturated fatty acid (SAFA) intake has also been found to be positively associated with plasma cholesterol concentrations in infants and children (Akerblom et al., 1985; Ohlund et al., 2008) .
Two studies have investigated the effect of dietary fatty acids on CVD risk factors in children through dietary counselling aimed at reducing SAFA and increasing PUFA intakes. The Dietary Intervention Study in Schoolchildren included 663 8-10-year-old children with moderately elevated LDL-cholesterol levels at baseline. The intervention group received a series of group and individual sessions of dietary counselling for a diet low in total fat (28%E), SAFA (8%E) and high in PUFA (up to 9%E), whereas the control group received general dietary information only. The intervention diet resulted in significantly lower LDL cholesterol after 3 years, but not after 5 years of follow-up. The authors suggested that the latter may have been because of difficulties in adherence to the diet in the intervention group (Obarzanek et al., 2001) .
The STRIP study aimed to reduce SAFA intake (o10%E) and increase PUFA intake (410%E) by dietary counselling from infancy onwards, and demonstrated that at 14 years of age and compared with the control group, children (both boys and girls) with a low-saturated-fat diet had lower LDL-cholesterol levels and lower blood pressure whereas lower serum triglyceride levels occurred only in boys (Niinikoski et al., 2007 .
A review of dietary surveys and population studies of fat and fatty acid intakes in children and adolescents worldwide found data for 28 countries; mainly from Europe, North America, Australia and New Zealand, with data for only four countries from other regions (Harika et al.,submitted for publication). Mean SAFA intakes were higher (410%E) in 26 out of 28 countries and PUFA intakes were lower (o6%E) in 21 out of 28 countries, than the population-based nutrient intake goals recommended by WHO for prevention of chronic diseases (WHO/FAO, 2003) . In particular ALA, DHA and EPA intakes were lower than that recommended for the prevention of CVD. Overall, these data suggest that the intakes of fatty acids in children and adolescents are not in line with recommendations for future cardiovascular health.
Future research from long-term follow-up studies is required to determine whether childhood interventions and specific EFA intakes in early childhood impact ultimate disease risk at adult age. In this regard, it would be useful to identify and validate surrogate markers for clinical disease end points in children. More research is required on the most effective timing of interventions during childhood. Recent evidence suggests that perhaps the most critical window for interventions aiming at prevention of chronic diseases is in early infancy and in utero , supporting the importance of a life-course perspective on prevention of future cardiometabolic diseases.
Essential fats for future health: a case studyDr Harri Niinikoski Individuals with high total-and LDL-cholesterol concentrations are predisposed to early atherosclerotic changes in aorta and large arteries already in childhood and adolescence. As fat quality greatly contributes to serum cholesterol levels at all ages, efforts should be made to improve fat quality from early years onwards. The Special Turku coronary Risk factor Intervention Project (STRIP) is a randomized intervention trial which was launched in 1990 to investigate whether atherosclerosis risk factors could be prevented in childhood by means of supervised dietary and lifestyle counselling (Simell et al., 2009) . The STRIP counselling aims at decreasing the intake of saturated fat while increasing the intake of unsaturated fat, that is, improving the fat quality. Thus, STRIP provides detailed data on the influences of lowsaturated-fat diet on dietary intakes, serum cholesterol concentration, and growth and development in healthy children and adolescents. The intervention and control groups consist of 540 and 522 children, respectively. After 1 year of age, the intervention children were advised to use skim or 1% fat milk and other low-fat dairy products and to add 2-3 teaspoons of vegetable oil (mainly low-erucic acid rapeseed oil) to their daily food. They were also advised to use vegetable oil and margarine in food preparation, on bread and so on. Compared with controls, the intervention children had B2E% lower saturated fat intake (Po0.001) and 0.1-0.2 mmol/l lower LDL-cholesterol values (Po0.001), whereas HDL-cholesterol values did not differ between the study groups (Niinikoski et al., 2007) . HDL-to-total cholesterol ratio was higher in the intervention children than in controls. The intervention had more effects on cholesterol concentrations in boys than in girls. The intervention did not influence growth or pubertal development in either sex (Niinikoski et al., 1997 (Niinikoski et al., , 2007 , but the intervention children had B1 mm Hg lower blood pressure throughout childhood than controls ). Detailed cognitive tests performed at the age of 5 years showed no differences between the two study groups (Rask-Nissila et al., 2000) . Thus, the STRIP data support the safety of supervised lowsaturated-fat diet in children.
Session 3. Joint solutions for future health
The third session was convened to discuss how public health policies are developed to improve the fat quality of the diet in children and adults. Professor Jantine Schuit provided a general overview on the challenges to translate scientific developments into public health strategies, with a specific focus on the work of the National Institute for Public Health and the Environment in the Netherlands. This topic was further illustrated by a presentation by Professor Pirjo Pietinen on the nutrition policies for prevention of CVD in Finland. Drs Leendert Wesdorp and Andy Porteous discussed the technological difficulties in designing healthy products containing a high PUFA content and the marketing opportunities for these products. The session ended with a call from Connie Diekman to unite academia, public health authorities and industry to effectively improve the public's health.
Translating scientific developments into public health strategies-Professor Jantine Schuit
The research, including monitoring, modelling and risk assessment, of the National Institute for Public Health and the Environment (RIVM) is used to support policy and practice in public health, food, safety and the environment. The task is to ensure that decision making in policy and practice is well informed by the best available (scientific) evidence.
In translating knowledge into policy and practice, it is important to understand the role of the actors and factors involved in the process and to take the context (political, public opinion, health care and so on) into account. Not only the question 'what is effective' but also questions such as 'why, how and under what circumstances is it working' should be answered. This could lead to improved effectiveness of innovations in public health and health care (Oxman et al., 2009) . Furthermore, it is important to recognize that (scientific) knowledge is only part of the policy decisionmaking process (Armstrong et al., 2006) . Other kinds of knowledge, such as values and policy context, resources, habits and culture, influence of lobbyist and pressure groups, experience and expertise have a role.
The likelihood of research being used by policymakers is increased when there is interaction between researchers and policymakers or professionals. Furthermore, the policy maker should have a positive attitude towards the relevance of research evidence. This may be difficult because the context in which policy makers or professionals operate is very different from a researcher. Whereas a policy maker has to deal with complex problems which need quick answers, has to be accountable for different parties and works in a dynamic world, the scientist usually investigates one problem very conscientiously, which takes time and often does not yield clear-cut answers. The uptake of knowledge can be enhanced by making knowledge more accessible and fit for purpose. This can be improved by closer interaction during the process of the identification of the research question, the research itself and the timing of the communication of key outcomes (Lomas, 2007) . Clear messages are needed that translate the research outcome for policy and practice, for example, can we relate the international experience to the local context, what is the feasibility (political, technical, costs and legal, community acceptance) of introducing innovations in the health system. However, during the process of interaction, the researcher has to retain independence, which sometimes may be challenging. To support evidence-informed policy and practice, the RIVM uses various approaches and strategies, including websites, knowledge brokering, appraisal systems, competence building and close collaboration with policy makers, health professionals and stakeholders during the research process. The challenge for institutes like the RIVM is to develop knowledge that is valid and robust, fitting the need, translatable, feasible and acceptable, and developed in close interaction with the policy makers, health professionals and other stakeholders, with a mutual goal and commitment.
Translating science into nutrition policy: Finland as an example-Professor Pirjo Pietinen
Finland has a long history of nutrition policy aiming at preventing CVD. The North Karelia Project, which was a community-based project in the early 1970s, was the starting point and a pilot project testing population-based strategies, which have then spread to the whole country involving the media, primary health care, food industry, catering and so on, to make healthy choices easy for the consumer, and building a monitoring system.
The National Institute for Health and Welfare, THL (former KTL) is responsible for CVD risk factor surveys (FINRISK surveys) carried out every 5 years in large crosssectional population samples in several areas since 1972 (Vartiainen et al., 2010) . In addition, an annual postal survey covering the whole country focuses on health behaviour. Dietary surveys (FINDIET surveys) have been carried out in connection with FINRISK Surveys since 1982. A separate, large population survey carried out by the National Insurance Institution in the early 1970s gives information on diet from that time.
Since the early 1970s, the Finnish diet has changed dramatically: the majority of people use skim or low-fat milk, oils for cooking and low-fat margarines on bread instead of butter and high-fat milk, and vegetable consumption has tripled. The most important oil used in the margarine industry as well as at home is rapeseed oil, which is also locally produced. The most often used margarines are now low-fat margarines, which have 30-60% fat content. Margarines with plant sterols or stanols have also gained popularity, one reason being that one brand has been developed in Finland. Skim milk is the most popular milk among women and over 90% of milk consumed has a fat content between 0.5-1.5%.
These changes are reflected in the fatty acid composition of the Finnish diet. The share of SAFA has decreased from 20 to 13%E, and that of PUFA has increased from 3 to 6%E. The share of monounsaturated fatty acids has remained about the same. The intake of total fat has decreased from about 38 to 33%E. Mean serum cholesterol has decreased from close to 7 mmol/l in North Karelian men in 1972 to 5.4 mmol/l in the same area. The differences between areas have diminished.
How much the dietary changes explain the decline in serum cholesterol has been analyzed from 1982 to 2007 (Valsta et al., 2010) . Predicted changes in serum cholesterol were calculated by the Keys' equation assuming the effect of trans-fatty acids to be similar to SAFA. The effect of medication was estimated based on the information on use of lipid-lowering medication among survey participants. Changes in dietary fat quality and cholesterol intake explain 0.70 mmol/l (65%) of the decrease in serum cholesterol in men and 0.65 mmol/l (60%) in women. Decline in SAFA intake is the main explanatory factor (47% in men and 41% in women) for the changes. The impact of lipid-lowering medication on observed cholesterol levels was found to be 16% among men and 7% among women.
Risk factor changes (decrease in serum cholesterol and blood pressure, and in the prevalence of smoking) explain about 60% of the reduction in coronary mortality over the period 1972-2007, although the observed reduction has been 80%. The most important risk factor in this analysis was clearly serum cholesterol. Thus, the favourable dietary changes have been the most important factor in this development. This success story has been possible, thanks to good cooperation between the many stakeholders involved. Nongovernmental organizations have been important, particularly the Finnish Heart Association and the Finnish Diabetes Association, which have together launched the Heart Symbol to be used on front of pack labelling. The symbol tells the consumer at a glance that the product marked with this symbol is a better choice in its product category. The right to use the Heart Symbol can be given in several different food categories and the criteria is concerned with the quantity and quality of fat, sodium, cholesterol, sugars, and fiber as is applicable in the product category. A group of professionals grants the rights upon application from the manufacturers and subsequent review. About 80% of the consumers recognize the symbol and 52% say that the symbol has influenced their purchases.
The catering sector, which offers a hot lunch from daycare to schools and worksites, has also had an important role. The National Nutrition Council, which gives dietary recommendations, also gives recommendations for the catering sector. On the basis of recent research, children in daycare have a healthier diet than children at home, and school lunch is the healthiest meal in the diet of 13-year olds.
The role of food industry has been very important, and healthier products such as low-fat cheeses and other dairy products, good quality margarines and so on have become increasingly available.
Translating scientific developments into sustainable consumer solutions-Dr Leendert Wesdorp and Andy Porteous
Even today, in essence, food culture remains quite traditional. Therefore, it is difficult to convince people to change their dietary habits to improve the quality of their diet. Fortification of foods is an effective strategy to improve the intakes of nutrients and usually does not have a large impact on food texture, such as iodized salt (Lotfi et al., 1996) . However, improving fat quality by replacing SAFA with PUFA in a product will dramatically change its properties. Whereas SAFA provide texture and palatability to a food, PUFA are liquid and easily give rancid off-flavours due to oxidation. Thus, developing attractive healthy foods with a high PUFA content has created a significant technical challenge for the food industry.
In margarines, the SAFA content can be reduced by re-arrangement of palm stearin and palm kernel-oil and use of a combination of long and medium chain fatty acids which give very small fat crystals that provide a similar texture with half the amount of SAFA (Dickinson and McClements, 1996) . To prevent oxidation of PUFA, vegetable oils are purified to remove oxidized components, their precursors and pro-oxidative trace metals from oil and processing equipment (Fe, Cu) . This can be realized by scavenging trace metals in the products using chelation with proteins and EDTA; addition of antioxidants such as vitamin C, vitamin E and herbal extracts; and by physical separation of pro-oxidants and PUFA in the product. To completely remove the remaining fat oxidation flavours, small amounts of low PUFA fat sources are selectively pre-oxidized before these are added to the product (de Deckere and Verschuren, 2000) .
Marketing of healthy products is directed to help people to make healthier choices within their current diet. The benefits of these products should be communicated through different media and communication channels and to different target audiences, including consumers, health-care professionals and scientists. In addition, positive endorsement of recognized public health authorities and clear regulation of health claims are required.
Achieving optimal intakes of EFAsConnie Diekman
Healthy eating involves choosing healthier fats in place of less healthy fats but research shows that most consumers continue to be confused about fat. A global study, done in 2007 and 2008, as a part of the International Experts Movement, found that fat is misunderstood by the majority of consumers (Diekman and Malcolm, 2009 ). The study was composed of 3200 subjects who were the main grocery shoppers for their families. The subjects were asked about information on fat and a majority, 57%, indicated that they felt the information on fat and health was contradictory. In addition, 52% did not know which fats were more healthful than others. This confusion among consumers makes it difficult for them to change behaviours and generally results in staying with the fat choices they are more comfortable with.
The food industry is working to provide more options for the consumer but faces challenges associated with palatability and performance of different fat sources, the cost of developing new products and how consumers will view a change or higher cost, and identifying which products are the right products. As health-care providers work to educate people about healthier fats, changes in science require ongoing education, which often isn't feasible given the time constraints on many health-care providers. Staying on top of new products is also difficult for health-care providers, making collaborative efforts the only way to improve understanding of fatty acids and the use of healthier fats.
Developing a plan for collaboration requires identification of the main players with some of the potentials being the food industry, schools, hospitals, health-care providers and communities. Working together these groups can agree on nutrition messages that are based on science, develop practical tips for consumers, change messages as science changes but with a message that conveys the science behind the change and finally, the important message of lifestyle eating patterns. A few examples of programs that are the result of a collaborative effort include the National Dairy Council, The National Football League and the US Department of Agriculture's Fuel Up to Play 60 program which focuses on nutrition and activity goals for school age children. Another program is the new Let's Move campaign started by United States First lady Michelle Obama. This program includes chefs through the Chef's Move to Schools segment, food companies, schools and community organizations. The American Dietetic Association Foundation, along with PE4Life and the American Council for Fitness and Nutrition started a Healthy Schools partnership in Kansas City, Missouri with a goal of changing eating and activity behaviours. Outcomes show an increase in knowledge, vegetable consumption and small changes in weight.
Making changes in fat intake requires collaboration from all segments on clear messages related to fat in a healthy diet. Understanding the process of change will also be important as new food products take time to develop and changing taste palates takes time. Continuing to study fats in terms of healthfulness, developing ways to change fat in foods that consumers love and the importance of smaller portions are important steps in achieving optimal fatty acid consumption. Finally, these collaborative steps will help consumers understand the role and value of fat in a healthful eating plan.
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